Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants

Slični predmeti

• Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants
  od: Zhengjun Cai, i dr.
  Izdano: (2026-01-01)
• Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
  od: Prakash Jadhav, i dr.
  Izdano: (2025-02-01)
• Naturally Occurring Mutations of SARS-CoV‑2 Main Protease Confer Drug Resistance to Nirmatrelvir
  od: Yanmei Hu, i dr.
  Izdano: (2023-07-01)
• Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes
  od: Jinlin Tan, i dr.
  Izdano: (2022-09-01)
• Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease
  od: Junshuai Wang, i dr.
  Izdano: (2026-01-01)